MA

Aura Biosciences to Participate in Upcoming Investor Conferences

Retrieved on: 
Wednesday, May 8, 2024
Citizenship, Cancer, Doctor of Philosophy, Conference, Webcast, Fireside chats, Flour

BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors designed to preserve the function of the organ with cancer, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in the following upcoming investor conferences:

Key Points: 
  • BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors designed to preserve the function of the organ with cancer, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in the following upcoming investor conferences:
    The Citizens JMP Life Sciences Conference on Monday, May 13, 2024.
  • Fireside Chat at 9:00 a.m.
  • ET.
  • TD Cowen 5th Annual Oncology Innovation Summit on Wednesday, May 29, 2024.

MKS Instruments Declares Quarterly Cash Dividend

Retrieved on: 
Wednesday, May 8, 2024
MKSI, MKS Instruments, Holding company

ANDOVER, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- MKS Instruments, Inc. (NASDAQ: MKSI), a global provider of enabling technologies that transform our world, today announced that its Board of Directors has authorized a quarterly cash dividend of $0.22 per share, payable on June 7, 2024, to shareholders of record as of May 28, 2024.

Key Points: 
  • ANDOVER, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- MKS Instruments, Inc. (NASDAQ: MKSI), a global provider of enabling technologies that transform our world, today announced that its Board of Directors has authorized a quarterly cash dividend of $0.22 per share, payable on June 7, 2024, to shareholders of record as of May 28, 2024.
  • Future dividend declarations, as well as the record and payment dates for such dividends, are subject to the final determination of the Company's Board of Directors.

Kymera Therapeutics to Participate in Upcoming May Investor Conferences

Retrieved on: 
Wednesday, May 8, 2024
Bank of America, News, Conference, BofA Securities, TPD, Therapy

WATERTOWN, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats at the following upcoming investor events:

Key Points: 
  • WATERTOWN, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats at the following upcoming investor events:
    BofA Securities 2024 Health Care Conference in Las Vegas, NV on May 15 at 4:20 p.m. PT; and
    TD Cowen 5th Annual Oncology Innovation Virtual Summit on May 28 at 1:30 p.m.
  • ET.
  • Live webcasts of the presentations will be available under “ News and Events ” in the Investors section of the Company’s website at www.kymeratx.com.
  • Replays of the webcasts will be archived and available following the events.

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of agilon health

Retrieved on: 
Wednesday, May 8, 2024
LLP, News, Advertising, Patient, Court, Health, Person, Pharmaceutical industry

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.

Key Points: 
  • Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • The truth about the higher medical costs that agilon had been facing began to emerge on November 2, 2023.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding agilon’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
  • The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com).

Omega Therapeutics Presents New Preclinical Data at ASGCT 2024 Demonstrating Tunable and Durable Upregulation of Gene Expression with Epigenomic Controllers

Retrieved on: 
Wednesday, May 8, 2024
OMEGA, Cell, ECS, Gene, Society, Gene expression, Messenger, Therapy, Vaccine

Additional OMEGA platform capabilities demonstrated, including reversible downregulation and multiplexed upregulation of gene expression

Key Points: 
  • Additional OMEGA platform capabilities demonstrated, including reversible downregulation and multiplexed upregulation of gene expression
    CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced the presentation of new preclinical data demonstrating durable and tunable bidirectional regulation of gene expression in cellular models at the pre-transcriptional level at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting, taking place in Baltimore, Maryland, May 7 – 11.
  • “These exciting new data underscore the versatile capabilities and power of our OMEGA platform,” said Thomas McCauley, Ph.D., Chief Scientific Officer of Omega Therapeutics.
  • “We have demonstrated preclinically that we can prospectively engineer epigenomic controllers to predictably and durably upregulate gene expression across a diverse range of gene types, including turning on inactivated genes, augmenting the expression of genes with low baseline expression levels, and leveraging existing genomic regulatory processes to boost expression.
  • Additionally, simultaneous targeting of two regulatory elements for the same gene with two separate ECs yielded a synergistic effect, more than doubling expression compared to single element targeting.

LPL Financial Closes Acquisition of Crown Capital Securities

Retrieved on: 
Wednesday, May 8, 2024
LPL Financial, SAN, Acquisition, LPL, Strategic management, Financial adviser

SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- LPL Financial LLC (“LPL Financial” or “LPL”) announced it has closed its acquisition of the wealth management business of Crown Capital Securities, L.P. (“Crown Capital” or “Crown”) a full-service broker-dealer and registered investment advisor (“RIA”) headquartered in Orange County, California.

Key Points: 
  • SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- LPL Financial LLC (“LPL Financial” or “LPL”) announced it has closed its acquisition of the wealth management business of Crown Capital Securities, L.P. (“Crown Capital” or “Crown”) a full-service broker-dealer and registered investment advisor (“RIA”) headquartered in Orange County, California.
  • "We continue to be impressed with Crown Capital's growth mindset and deep commitment to the value of independence for financial advisors," said Rich Steinmeier, LPL Financial managing director and divisional president, Business Strategy & Growth.
  • "Through LPL's advisor-first focus and by leveraging our innovative platform and specialized services, the high-performing advisors at Crown Capital Securities are even better positioned to scale their thriving businesses."
  • “Since the inception of Crown Capital Securities, our ambition has been to offer best-in-class experiences to our advisors built upon our unique family culture and their clients while sustainably growing our business for the future,” said Jonathan L. French, Crown Capital president and chief marketing officer.

Voyager Therapeutics Presents Data for Second-Generation, TRACER™-Generated Capsids and CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting

Retrieved on: 
Wednesday, May 8, 2024
TRACER, Brain, Traffic barrier, Cell, Mouse, Neuron, Tropism, Machine learning, RNA, B cell, AAV, Voyager, IND, CNS, Alkaline phosphatase, Crab-eating macaque, Human, DNA, Therapy, Astrocyte, Gene, Society, ALS, Spinal cord, BBB, DSM-IV codes, Central nervous system, Messenger, Capsid, Transcytosis, NHP, ALPL, HEK293, Centrifuge, SOD1, Vaccine

LEXINGTON, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the presentation of data related to its TRACER™ capsid discovery platform and TRACER-driven gene therapy programs at the American Society of Gene & Cell Therapy’s (ASGCT) 27th annual meeting.

Key Points: 
  • Voyager identified a highly conserved cell surface receptor that mediates enhanced brain tropism of the VCAP-101/102 engineered capsid class.
  • Voyager has advanced machine learning to predict production fitness of capsid variants with high accuracy, helping guide development of high-production-fit libraries.
  • Robust manufacturing processes are needed to remove empty and partially filled capsids from recombinant AAV (rAAV) drug product.
  • This cost-efficient cell line provides an AAV expression platform to produce drug candidates for neurological disorders.

Arbor Biotechnologies Announces Acquisition of Serendipity

Retrieved on: 
Wednesday, May 8, 2024
Harvard University, Exon, CRISPR, Broad Institute, Gene editing, RNA, Acquisition, Gene, MIT

CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Arbor Biotechnologies, Inc., a biotechnology company discovering and developing the next generation of genetic medicines, today announced the acquisition of Serendipity Biosciences, a private biotechnology company focused on the discovery of unique gene editing technologies.

Key Points: 
  • CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Arbor Biotechnologies, Inc., a biotechnology company discovering and developing the next generation of genetic medicines, today announced the acquisition of Serendipity Biosciences, a private biotechnology company focused on the discovery of unique gene editing technologies.
  • Serendipity’s novel editing technologies were discovered in the lab of leading gene editing researcher and Arbor Biotechnologies co-founder, Feng Zhang, of the McGovern Institute for Brain Research at MIT and the Broad Institute of MIT and Harvard.
  • The innovative assets, which include Fanzor-based, IsrB-based, and additional undisclosed programmable editing technologies, complement and expand Arbor’s existing editing capabilities.
  • Our primary focus is on developing novel therapies for indications in the liver and CNS with significant unmet need while partnering in other areas,” said Devyn Smith, Ph.D., Chief Executive Officer of Arbor Biotechnologies.

Fulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy (ReDUX4) in The Lancet Neurology

Retrieved on: 
Wednesday, May 8, 2024
Losmapimod, Fulcrum, Abdomen, NDA, The Lancet, Muscle weakness, REACH, Lancet Neurology, Disability, DUX4, Disease, Patient, FSHD, Face, Gene expression, Clinical trial, Therapy, File, Atrophy

CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced the publication of results from its Phase 2b clinical trial of losmapimod for the treatment of facioscapulopumeral muscular dystrophy (FSHD). The data are published in the peer-reviewed journal The Lancet Neurology.

Key Points: 
  • The data are published in the peer-reviewed journal The Lancet Neurology .
  • No serious adverse events related to the drug were reported, and there were no discontinuations of treatment due to adverse events.
  • In September 2023, Fulcrum announced the enrollment completion for the Phase 3 clinical trial evaluating losmapimod in patients with FSHD at sites in the United States, Canada, and Europe.
  • The clinical trial remains on track with topline data expected in Q4 2024.

Jnana Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference

Retrieved on: 
Wednesday, May 8, 2024
Therapy, Conference

BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Jnana Therapeutics , a clinical-stage biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines for challenging-to-drug targets, today announced that Joanne Kotz, Ph.D., Co-founder and Chief Executive Officer, will present a corporate overview at the RBC Capital Markets Global Healthcare Conference on Tuesday, May 14, 2024 at 2:05 p.m.

Key Points: 
  • BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Jnana Therapeutics , a clinical-stage biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines for challenging-to-drug targets, today announced that Joanne Kotz, Ph.D., Co-founder and Chief Executive Officer, will present a corporate overview at the RBC Capital Markets Global Healthcare Conference on Tuesday, May 14, 2024 at 2:05 p.m.
  • ET.